$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924006121 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$43.77M	$72.18M	$235.6M
YoY Change	-17.07%	9.9%	3.34%
Cost Of Revenue	$10.73M	$24.32M	$62.68M
YoY Change	-18.84%	44.47%	13.77%
Gross Profit	$33.04M	$47.86M	$173.0M
YoY Change	-16.48%	-2.01%	0.01%
Gross Profit Margin	75.49%	66.3%	73.4%
Selling, General & Admin	$21.75M	$20.18M	$89.93M
YoY Change	-3.27%	-19.39%	-0.05%
% of Gross Profit	65.83%	42.18%	52.0%
Research & Development	$13.59M	$12.87M	$50.38M
YoY Change	6.93%	-6.61%	-3.56%
% of Gross Profit	41.13%	26.9%	29.13%
Depreciation & Amortization	$100.0K	$2.889M	$400.0K
YoY Change	0.0%	30.9%	-33.33%
% of Gross Profit	0.3%	6.04%	0.23%
Operating Expenses	$35.34M	$33.06M	$140.3M
YoY Change	0.41%	-14.85%	-1.34%
Operating Profit	-$2.299M	$14.80M	$32.64M
YoY Change	-152.67%	47.74%	37.61%
Interest Expense	$3.359M	-$2.635M	$13.33M
YoY Change	1.42%	-4.53%	14.99%
% of Operating Profit		-17.81%	40.84%
Other Income/Expense, Net	-$2.296M	$641.0K	-$9.966M
YoY Change	-18.49%	-414.22%	-57.16%
Pretax Income	-$4.595M	$12.80M	$22.67M
YoY Change	-396.83%	-341.04%	4861.49%
Income Tax	$220.0K	$536.0K	$1.083M
% Of Pretax Income		4.19%	4.78%
Net Earnings	-$4.815M	$12.27M	$21.60M
YoY Change	-443.68%	-318.84%	1079900.0%
Net Earnings / Revenue	-11.0%	17.0%	9.17%
Basic Earnings Per Share	-$0.10		$0.46
Diluted Earnings Per Share	-$0.10	$0.26	$0.45
COMMON SHARES
Basic Shares Outstanding	48.21M	47.57M	47.13M
Diluted Shares Outstanding	48.19M		47.55M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.2M	$95.94M	$95.94M
YoY Change	50.47%	18.34%	18.34%
Cash & Equivalents	$76.75M	$84.59M	$84.59M
Short-Term Investments	$30.41M	$11.35M	$11.35M
Other Short-Term Assets	$255.0K	$912.0K	$5.329M
YoY Change	-43.21%	-62.45%	-16.88%
Inventory	$7.100M	$7.080M	$7.080M
Prepaid Expenses	$3.924M	$4.417M
Receivables	$24.58M	$47.84M	$26.79M
Other Receivables	$0.00	$21.05M	$21.05M
Total Short-Term Assets	$143.0M	$156.2M	$156.2M
YoY Change	27.98%	16.31%	16.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$757.0K	$855.0K	$8.647M
YoY Change	-25.71%	-25.39%	-30.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.907M	$4.825M	$4.825M
YoY Change	5.3%	3.54%	3.54%
Total Long-Term Assets	$71.12M	$74.34M	$74.34M
YoY Change	-15.83%	-15.31%	-15.31%
TOTAL ASSETS
Total Short-Term Assets	$143.0M	$156.2M	$156.2M
Total Long-Term Assets	$71.12M	$74.34M	$74.34M
Total Assets	$214.1M	$230.5M	$230.5M
YoY Change	9.12%	3.81%	3.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.964M	$6.889M	$6.889M
YoY Change	4.37%	6.97%	6.97%
Accrued Expenses	$37.72M	$52.72M	$57.52M
YoY Change	10.49%	-0.59%	-17.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$45.33M	$34.00M	$34.00M
YoY Change
Total Short-Term Liabilities	$98.19M	$99.38M	$99.38M
YoY Change	103.77%	28.26%	28.26%
LONG-TERM LIABILITIES
Long-Term Debt	$54.69M	$65.66M	$65.66M
YoY Change	-44.55%	-33.21%	-33.21%
Other Long-Term Liabilities	$10.29M	$12.05M	$12.05M
YoY Change	-56.42%	-51.16%	-51.16%
Total Long-Term Liabilities	$54.69M	$65.66M	$77.70M
YoY Change	-44.55%	-33.21%	-36.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$98.19M	$99.38M	$99.38M
Total Long-Term Liabilities	$54.69M	$65.66M	$77.70M
Total Liabilities	$163.2M	$177.1M	$177.1M
YoY Change	-4.25%	-11.66%	-11.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.350B	-$1.345B
YoY Change	-1.13%	-1.58%
Common Stock	$1.401B	$1.399B
YoY Change	0.7%	0.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.98M	$53.44M	$53.44M
YoY Change
Total Liabilities & Shareholders Equity	$214.1M	$230.5M	$230.5M
YoY Change	9.12%	3.81%	3.81%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.815M	$12.27M	$21.60M
YoY Change	-443.68%	-318.84%	1079900.0%
Depreciation, Depletion And Amortization	$100.0K	$2.889M	$400.0K
YoY Change	0.0%	30.9%	-33.33%
Cash From Operating Activities	$11.20M	$10.46M	$27.00M
YoY Change	330.77%	36.08%	-270.89%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$45.00K	$140.0K
YoY Change	-100.0%	-99.36%
Acquisitions
YoY Change
Other Investing Activities	-$19.08M	-$8.125M	-$6.485M
YoY Change	285.45%	66.74%	-145.98%
Cash From Investing Activities	-$19.08M	-$8.170M	-$19.13M
YoY Change	9.34%	-31.19%	-369.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$0.00
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	$11.20M	10.46M	$27.00M
Cash From Investing Activities	-$19.08M	-8.170M	-$19.13M
Cash From Financing Activities	$0.00	0.000	$0.00
Net Change In Cash	-$7.834M	2.285M	$7.884M
YoY Change	-47.09%	-229.9%	125.26%
FREE CASH FLOW
Cash From Operating Activities	$11.20M	$10.46M	$27.00M
Capital Expenditures	$0.00	$45.00K	$140.0K
Free Cash Flow	$11.20M	$10.41M	$26.86M
YoY Change	-213.13%	1424.16%	-270.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53034000	usd
CY2023Q4	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	0	usd
CY2022Q4	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	12500000	usd
CY2023Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	975000	usd
CY2022Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1370000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4800000	usd
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	true
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	881000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47646787
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47646787
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46345660
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46345660
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9700000	usd
CY2023Q4	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	9700000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	500000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	500000	usd
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35703
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0683487
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	10880 Wilshire Boulevard, Suite 2150
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2023	dei	City Area Code CityAreaCode	424
CY2023	dei	Local Phone Number LocalPhoneNumber	248-6500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	PBYI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	141400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48207162
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84585000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76201000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11354000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4873000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47837000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40350000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7080000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4526000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4417000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5902000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	912000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2429000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	156185000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	134281000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7792000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11362000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1146000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60871000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	70610000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2091000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2591000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2734000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2069000	usd
CY2023Q4	us-gaap	Assets Assets	230528000	usd
CY2022Q4	us-gaap	Assets Assets	222059000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6889000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6440000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53034000	usd
CY2023Q4	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	0	usd
CY2022Q4	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	12500000	usd
CY2023Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	975000	usd
CY2022Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1370000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4800000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4140000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33997000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	99382000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77484000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	7391000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7034000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11834000	usd
CY2022Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5435000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	65659000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98307000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	177086000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	200451000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1398605000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1388358000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1345164000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1366755000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230528000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	235637000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	253155000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62682000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55093000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	63701000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89933000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89978000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	116294000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	50382000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	52240000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	71870000	usd
CY2023	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2021	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	202997000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	204311000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	251865000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	32640000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	23720000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1290000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2605000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	813000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	160000	usd
CY2023	us-gaap	Interest Expense InterestExpense	13330000	usd
CY2022	us-gaap	Interest Expense InterestExpense	11592000	usd
CY2021	us-gaap	Interest Expense InterestExpense	12807000	usd
CY2023	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4140000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33997000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	99382000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77484000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	7391000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7034000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11834000	usd
CY2023Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	4890000	usd
CY2022Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5435000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	65659000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98307000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	177086000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	200451000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1398605000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1388358000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1345164000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1366755000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230528000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	222059000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	235637000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	228031000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	253155000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62682000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55093000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	63701000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89933000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89978000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	116294000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	50382000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	52240000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	71870000	usd
CY2023	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2021	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	204311000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	251865000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	32640000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	23720000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	1290000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2605000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	813000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	160000	usd
CY2023	us-gaap	Interest Expense InterestExpense	13330000	usd
CY2022	us-gaap	Interest Expense InterestExpense	11592000	usd
CY2021	us-gaap	Interest Expense InterestExpense	12807000	usd
CY2023	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	0	usd
CY2022	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-12456000	usd
CY2021	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-9591000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	292000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9966000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23263000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30092000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22674000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	457000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28802000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47134331
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44674501
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40638852
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21587000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29128000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32633000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11826000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12224000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10247000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-12456000	usd
CY2021	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-9591000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
CY2021	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	759000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9966000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23263000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30092000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22674000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	457000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28802000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47134331
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44674501
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40638852
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47550852
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44929998
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40638852
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21587000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29128000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32633000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11826000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12224000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10247000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21591000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11519000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11305000	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2021	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10247000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11826000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	32633000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	881000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	625000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8146000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8368000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7824000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5983000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2554000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2583000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3655000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-820000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2367000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2669000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1517000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1982000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3194000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	449000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4734000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-902000	usd
CY2023	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	1195000	usd
CY2022	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	920000	usd
CY2021	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	707000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7583000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-33065000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5209000	usd
CY2023	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-940000	usd
CY2022	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-921000	usd
CY2021	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-1134000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27009000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15827000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20650000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	140000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29126000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11519000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9840000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11305000	usd
CY2023	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2021	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10247000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11826000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	625000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8146000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8368000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7824000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5983000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2554000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2583000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3655000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-820000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2669000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1517000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1982000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3194000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4734000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-902000	usd
CY2023	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	1195000	usd
CY2022	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	920000	usd
CY2021	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	707000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7583000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-33065000	usd
CY2023	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-940000	usd
CY2022	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-921000	usd
CY2021	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-1134000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27009000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15827000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	140000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	-0	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	7000000	usd
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	-0	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	23813000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4836000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38073000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	17328000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	-0	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	7000000	usd
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	-0	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	23813000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4836000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38073000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	17328000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	18940000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27192000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12500000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19125000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7104000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10881000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	12500000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	98500000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000000	usd
CY2023	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	-0	usd
CY2022	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	-0	usd
CY2021	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	8521000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1910000	usd
CY2023	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	-0	usd
CY2021	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	20000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7884000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3500000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78792000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86676000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78792000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	12500000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	11628000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	10319000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10342000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	737000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	18940000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27192000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12500000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19125000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7104000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10881000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	12500000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	277000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	98500000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000000	usd
CY2023	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	-0	usd
CY2022	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	-0	usd
CY2021	pbyi	Payment For Debt Extinguishment Debt Prepayment Cost And Other Extinguishment Costs PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts	8521000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2023	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	-0	usd
CY2022	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	-0	usd
CY2021	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	20000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12223000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-31931000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7884000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3500000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22162000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78792000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86676000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78792000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	12500000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	11628000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	10319000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10342000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	737000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	384000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	324000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	384000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	324000	usd
CY2023	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2023Q4	pbyi	Upfront License Fee UpfrontLicenseFee	7000000	usd
CY2023Q4	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	287300000	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21600000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27000000	usd
CY2023Q4	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	95900000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Reclassifications</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported results of operations. An adjustment to the presentation of operating lease assets and liabilities, net has been made to the Consolidated Statements of Cash Flows for the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. Other significant estimates also include those related to legal and other expense accruals. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2023Q4	pbyi	Upfront License Fee UpfrontLicenseFee	7000000	usd
CY2023Q4	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	287300000	usd
CY2022	pbyi	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	7000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	21600000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27000000	usd
CY2023Q4	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	95900000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Reclassifications</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported results of operations. An adjustment to the presentation of operating lease assets and liabilities, net has been made to the Consolidated Statements of Cash Flows for the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. Other significant estimates also include those related to legal and other expense accruals. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6929970000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8110814000
CY2023Q4	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6929970000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6806839000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8110814000
CY2023Q4	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2100000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2600000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2100000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2600000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	48916000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	usd
CY2023Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	48912000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	46546000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	usd
CY2022Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	46546000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Risk</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> December 31, 2023</em>, were approximately $84.4 million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for credit loss primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0.9 million credit loss expense in the year ended <em style="font: inherit;"> December 31, 2023, </em>and no such expense in the year ended <em style="font: inherit;"> December 31, 2022. </em>The Company recorded a recovery of credit loss expense of $1.0 million in year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022,</em> accounts receivable from individual customers with balances due in excess of <em style="font: inherit;">10%</em> of total accounts receivable totaled $32.3 million and $28.9 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were developed by Pfizer, both the drug substance and drug product are manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	84400000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	900000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5693000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1679000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	820000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2661000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	567000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	186000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7080000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4526000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	48916000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2023Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	48912000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	46546000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	usd
CY2022Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	46546000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Risk</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> December 31, 2023</em>, were approximately $84.4 million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for credit loss primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0.9 million credit loss expense in the year ended <em style="font: inherit;"> December 31, 2023, </em>and no such expense in the year ended <em style="font: inherit;"> December 31, 2022. </em>The Company recorded a recovery of credit loss expense of $1.0 million in year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 28pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022,</em> accounts receivable from individual customers with balances due in excess of <em style="font: inherit;">10%</em> of total accounts receivable totaled $32.3 million and $28.9 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were developed by Pfizer, both the drug substance and drug product are manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	84400000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	900000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5693000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1679000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	820000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2661000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	567000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	186000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7080000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4526000	usd
CY2023Q4	pbyi	Cares Act Credit Receivable CaresActCreditReceivable	0	usd
CY2022Q4	pbyi	Cares Act Credit Receivable CaresActCreditReceivable	1920000	usd
CY2023Q4	pbyi	Reimbursement Recieavble ReimbursementRecieavble	652000	usd
CY2022Q4	pbyi	Reimbursement Recieavble ReimbursementRecieavble	0	usd
CY2023Q4	pbyi	Receivable Other ReceivableOther	260000	usd
CY2022Q4	pbyi	Receivable Other ReceivableOther	509000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	912000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2429000	usd
CY2023Q4	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	9700000	usd
CY2023Q4	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	2400000	usd
CY2023Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	27669000	usd
CY2023Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	21049000	usd
CY2023Q4	pbyi	Cares Act Credit Receivable CaresActCreditReceivable	0	usd
CY2022Q4	pbyi	Cares Act Credit Receivable CaresActCreditReceivable	1920000	usd
CY2023Q4	pbyi	Reimbursement Recieavble ReimbursementRecieavble	652000	usd
CY2022Q4	pbyi	Reimbursement Recieavble ReimbursementRecieavble	0	usd
CY2023Q4	pbyi	Receivable Other ReceivableOther	260000	usd
CY2022Q4	pbyi	Receivable Other ReceivableOther	509000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	912000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2429000	usd
CY2023Q4	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000000	usd
CY2023Q4	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	2400000	usd
CY2022Q4	pbyi	Payroll Tax Credit PayrollTaxCredit	3800000	usd
CY2022Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	12750000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	48718000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	40350000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	881000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	-0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	47837000	usd
CY2023Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	27669000	usd
CY2022Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	27600000	usd
CY2023Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	21049000	usd
CY2022Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	12750000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	48718000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	40350000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	881000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	-0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	47837000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	40350000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	900000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	6000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	40350000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	900000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	usd
CY2023Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	6000	usd
CY2022Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	431000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	534000	usd
CY2022Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	1408000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1403000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2318000	usd
CY2023Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	1081000	usd
CY2022Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	300000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1393000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1445000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4417000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5902000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	210000	usd
CY2022Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2524000	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2734000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7151000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7971000	usd
CY2022Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	431000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	534000	usd
CY2022Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	1408000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1403000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2318000	usd
CY2023Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	1081000	usd
CY2022Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	300000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1393000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5902000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	210000	usd
CY2022Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2524000	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2734000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2069000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7151000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7971000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8535000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8572000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7680000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7426000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1146000	usd
CY2023	us-gaap	Depreciation Depreciation	400000	usd
CY2022	us-gaap	Depreciation Depreciation	600000	usd
CY2021	us-gaap	Depreciation Depreciation	700000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	5100000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8535000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8572000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7680000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7426000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1146000	usd
CY2022	us-gaap	Depreciation Depreciation	600000	usd
CY2021	us-gaap	Depreciation Depreciation	700000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	5100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5983000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1508000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13296000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1462000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11834000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	500000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1013000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1044000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	266000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2323000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6084000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2022Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	553000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	513000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53034000	usd
CY2023Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	0	usd
CY2022Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	7354000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5805000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5983000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1508000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13296000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1462000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	500000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1044000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	266000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2323000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6084000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41629000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31890000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60871000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	70610000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41629000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31890000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60871000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	70610000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	12176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60871000	usd
CY2023Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	7706000	usd
CY2022Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	8000000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16496000	usd
CY2023Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	940000	usd
CY2022Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	1796000	usd
CY2023Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	9388000	usd
CY2022Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	12304000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5900000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7667000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4379000	usd
CY2023Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1044000	usd
CY2022Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1233000	usd
CY2023Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	245000	usd
CY2022Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1649000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1589000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1731000	usd
CY2023Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	4521000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9739000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	12176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60871000	usd
CY2023Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	7706000	usd
CY2022Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	8000000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16496000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13585000	usd
CY2023Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	940000	usd
CY2022Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	1796000	usd
CY2023Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	9388000	usd
CY2022Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	12304000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5900000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7667000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4379000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4301000	usd
CY2023Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1044000	usd
CY2022Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1233000	usd
CY2023Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	245000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1589000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1731000	usd
CY2023Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	4521000	usd
CY2022Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	553000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	513000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53034000	usd
CY2023Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	0	usd
CY2022Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	7354000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	7391000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2022Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	7391000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	52842000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	60425000	usd
CY2023Q4	pbyi	Restructuring Percentage Of Reduction In Headcount RestructuringPercentageOfReductionInHeadcount	0.05	pure
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2344000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33997000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	65659000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	33997000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	45329000	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3066000	usd
CY2022Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	1717000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2344000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1300000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1200000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2600000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10247000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	52842000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	60425000	usd
CY2023Q4	pbyi	Restructuring Percentage Of Reduction In Headcount RestructuringPercentageOfReductionInHeadcount	0.05	pure
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2344000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	33997000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	45329000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	22674000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	102000000	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3066000	usd
CY2022Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	1717000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2344000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3693000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1300000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1200000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2600000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11826000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32633000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.9
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10247000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11826000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32633000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.9
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	835297
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.76
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	582353
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	618274
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.61
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	799376
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	581614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	674010
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.15
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	706980
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.46
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	835297
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.76
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	582353
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	618274
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.61
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	799376
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	581614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	674010
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.15
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	706980
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.46
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	905000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	363000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	77000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	178000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	92000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	247000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	4200000	usd
CY2023	pbyi	Income Tax Benefit Due To Research And Development Tax Credits IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits	1800000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	500000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4488000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	96000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6045000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1312000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	485000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1072000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	92000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	247000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	4837000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6864000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	22689000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1806000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1490000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	363000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	77000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	178000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	92000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	247000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	4200000	usd
CY2023	pbyi	Income Tax Benefit Due To Research And Development Tax Credits IncomeTaxBenefitDueToResearchAndDevelopmentTaxCredits	1800000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	500000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4488000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	96000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6045000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1312000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	485000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1072000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	178000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	92000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	247000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	4837000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6864000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	22689000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1806000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1490000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1715000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3941000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1715000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-455000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	916000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6211000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5137000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-12470000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	240960000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	253544000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	258390000	usd
CY2023Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	62051000	usd
CY2022Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	59726000	usd
CY2021Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	59514000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	37946000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	37876000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	40647000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19882000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10371000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2023Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	261000	usd
CY2022Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	3878000	usd
CY2021Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	14144000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1477000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4761000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4537000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1976000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	50000	usd
CY2023Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	3034000	usd
CY2022Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	4035000	usd
CY2021Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	4839000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3560000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1306000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	371818000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	377801000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	383481000	usd
CY2023Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	1997000	usd
CY2022Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	2870000	usd
CY2021Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	3470000	usd
CY2023Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	921000	usd
CY2022Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	-242000	usd
CY2021Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	-406000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	149000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	211000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	318000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3382000	usd
CY2023Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	368751000	usd
CY2022Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	374962000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-455000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	916000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6211000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5137000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-12470000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1083000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	455000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	324000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	240960000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	253544000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	258390000	usd
CY2022Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	59726000	usd
CY2021Q4	pbyi	Deferred Tax Assets Business Credit Carryforward DeferredTaxAssetsBusinessCreditCarryforward	59514000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	37876000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	40647000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19882000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10371000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2023Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	261000	usd
CY2022Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	3878000	usd
CY2021Q4	pbyi	Deferred Tax Assets Accrued Legal Verdict DeferredTaxAssetsAccruedLegalVerdict	14144000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1477000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4761000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4537000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1976000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	50000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	104000	usd
CY2023Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	3034000	usd
CY2022Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	4035000	usd
CY2021Q4	pbyi	Deferred Tax Asset Lease Liabilities DeferredTaxAssetLeaseLiabilities	4839000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4231000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3560000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1306000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	371818000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	377801000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	383481000	usd
CY2021Q4	pbyi	Deferred Tax Liabilities Lease Right Of Use Asset DeferredTaxLiabilitiesLeaseRightOfUseAsset	3470000	usd
CY2023Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	921000	usd
CY2022Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	-242000	usd
CY2021Q4	pbyi	Deferred Tax Liabilities Assets Inventory DeferredTaxLiabilitiesAssetsInventory	-406000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	149000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	211000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	318000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3067000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2839000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3382000	usd
CY2023Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	368751000	usd
CY2022Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	374962000	usd
CY2021Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	380099000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	368751000	usd
CY2021Q4	pbyi	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	380099000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	368751000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	374962000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	380099000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2522000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4261000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3276000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	163000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2113000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	-0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	452000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	374000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	985000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2811000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2522000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4261000	usd
CY2014Q3	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	usd
CY2023Q4	pbyi	Potential Milestone Payments PotentialMilestonePayments	102500000	usd
CY2022	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625	pure
CY2021Q3	pbyi	Milestone Payment MilestonePayment	1800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	374962000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	380099000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5100000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4261000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3276000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	163000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2113000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	-0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	452000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	374000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	985000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2811000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2522000	usd
CY2014Q3	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	usd
CY2023Q4	pbyi	Potential Milestone Payments PotentialMilestonePayments	102500000	usd

Files In Submission

Name	View Source	Status
0001437749-24-006121-index-headers.html	Edgar Link	pending
0001437749-24-006121-index.html	Edgar Link	pending
0001437749-24-006121.txt	Edgar Link	pending
0001437749-24-006121-xbrl.zip	Edgar Link	pending
ex_607302.htm	Edgar Link	pending
ex_607303.htm	Edgar Link	pending
ex_607304.htm	Edgar Link	pending
ex_607305.htm	Edgar Link	pending
ex_607306.htm	Edgar Link	pending
ex_607307.htm	Edgar Link	pending
ex_627486.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20231231.xsd	Edgar Link	pending
pbyi20231231_10k.htm	Edgar Link	pending
pipeline22424rdg.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
pbyi-20231231_cal.xml	Edgar Link	unprocessable
pbyi-20231231_def.xml	Edgar Link	unprocessable
pbyi-20231231_lab.xml	Edgar Link	unprocessable
pbyi20231231_10k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
yearperfsized4.jpg	Edgar Link	pending
0001437749-24-006121-index-headers.html	Edgar Link	pending
0001437749-24-006121-index.html	Edgar Link	pending
0001437749-24-006121.txt	Edgar Link	pending
0001437749-24-006121-xbrl.zip	Edgar Link	pending
ex_607302.htm	Edgar Link	pending
ex_607303.htm	Edgar Link	pending
ex_607304.htm	Edgar Link	pending
ex_607305.htm	Edgar Link	pending
ex_607306.htm	Edgar Link	pending
ex_607307.htm	Edgar Link	pending
ex_627486.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20231231.xsd	Edgar Link	pending
pbyi20231231_10k.htm	Edgar Link	pending
pipeline22424rdg.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
pbyi-20231231_cal.xml	Edgar Link	unprocessable
pbyi-20231231_def.xml	Edgar Link	unprocessable
pbyi-20231231_lab.xml	Edgar Link	unprocessable
pbyi20231231_10k_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
yearperfsized4.jpg	Edgar Link	pending
pbyi-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pbyi-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2024 Q1 Form 10-K Financial Statement

#000143774924006121 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2024 Q1 Form 10-K Financial Statement

#000143774924006121 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi